Himalaya Drug Company Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 05-12-2024
- Paid Up Capital ₹ 1.00 M
as on 05-12-2024
- Company Age 27 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 161.61 Cr
as on 05-12-2024
- Revenue 19.20%
(FY 2022)
- Profit 19.43%
(FY 2022)
- Ebitda 0.11%
(FY 2022)
- Net Worth 31.20%
(FY 2022)
- Total Assets 31.20%
(FY 2022)
About Himalaya Drug Company
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹161.61 Cr.
Syed Ahmed, Jayashree Ullal, and Karagadde Umesh serve as directors at the Company.
- CIN/LLPIN
U24232KA1997PTC022261
- Company No.
022261
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 May 1997
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Himalaya Drug Company Private Limited offer?
Himalaya Drug Company Private Limited offers a wide range of products and services, including Pure Herbs, Brahmi, Cosmetics Beauty, Deep Cleansing Milk, Pipe, Ppr Reducing Tee, Pharma Services, Mail Order Pharmacy, Print, Kbi Chemical.
Who are the key members and board of directors at Himalaya Drug Company?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Syed Ahmed  | Director | 31-Oct-1997 | Current |
| Jayashree Ullal | Director | 09-Jan-2009 | Current |
| Karagadde Umesh | Director | 31-Aug-2020 | Current |
Financial Performance and Corporate Structure Insights of Himalaya Drug Company.
Himalaya Drug Company Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 19.2% increase. The company also saw a substantial improvement in profitability, with a 19.43% increase in profit. The company's net worth Soared by an impressive increase of 31.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Himalaya Drug Company?
In 2022, Himalaya Drug Company had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Union Bank Of India Creation Date: 27 Mar 2006 | ₹161.61 Cr | Open |
How Many Employees Work at Himalaya Drug Company?
Unlock and access historical data on people associated with Himalaya Drug Company, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Himalaya Drug Company, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Himalaya Drug Company's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
